

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
31 December 2003 (31.12.2003)

PCT

(10) International Publication Number
WO 2004/000799 A1

(51) International Patent Classification: **C07C 409/32, 409/38, C08F 4/32, 4/38** (74) Agent: **SCHALKWIJK, Pieter, Cornelis; Akzo Nobel N.V., Intellectual Property Department (Dept. AIP), P.O. Box 9300, NL-6800 SB Arnhem (NL).**

(21) International Application Number:
PCT/EP2003/006339

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: **13 June 2003 (13.06.2003)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/390,799 20 June 2002 (20.06.2002) US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: **AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL).**

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A1

WO 2004/000799

(54) Title: (STABILISED) PEROXIDE COMPOSITIONS PHLEGMATISED WITH A SPECIFIC UNSATURATED PHLEGMATISING AGENT

(57) Abstract: The invention relates to peroxide compositions that are phlegmatised with a specific unsaturated phlegmatising agent. The phlegmatised peroxide compositions are optionally stabilised. In addition, the invention relates to the safe handling of these peroxide compositions and the use of these peroxide compositions in polymerisation processes..

(STABILISED) PEROXIDE COMPOSITIONS PHLEGMATISED WITH A
SPECIFIC UNSATURATED PHLEGMATISING AGENT

5 The invention relates to phlegmatised peroxide compositions that are optionally stabilised, that can be handled, produced, and shipped in a safe manner. It also relates to the safe use of such peroxides compositions in polymerisation processes where the resulting polymer preferably has a reduced level of undesired residues of low-molecular weight and/or inert phlegmatising agents.

10

Stabilised peroxide compositions, such as peroxydicarbonate compositions, have been disclosed before:

- In the Journal of the American Chemical Society, Volume 72, pp. 1254-1263 (1950) it is mentioned that the decomposition of diisopropyl peroxydicarbonate is retarded by the addition thereto of substances such as iodine, phenol, hydroquinone, salicylic acid, nitromethane, pyrogallol, cyclohexene, or hydrogen peroxide (HOOH).
- US 5,155,192 discloses the use of organic hydroperoxides (ROOH, wherein R represents an organic group) for the stabilisation of peroxydicarbonates.
- US 5,892,090-A1 describes the stabilisation of peroxydicarbonates against decomposition by the presence of an effective amount of one or more oximes.
- JP 10,059,933-A discloses that decomposition of peroxydicarbonates can be retarded with beta-dicarbonyl, or cyclic alpha-diketone compounds.
- JP 10,059,932-A describes the stabilisation of peroxydicarbonate by using phosphomolybdic acid.

25 Due to the safety hazards associated with most (organic) peroxides, they are often diluted with one or more specific solvents, also known as phlegmatisers. Classical phlegmatising agents are hydrocarbons and esters, such as phthalates. The use of phlegmatising agents for (organic) peroxides has been

disclosed before:

- US 4,131,728 discloses a polymerisation process employing shock-sensitive peroxides in improved phlegmatisers. The improved phlegmatisers are specific monomers that do not homopolymerise.
- 5 Exemplified suitable phlegmatising monomers are maleic and citraconic anhydride and esters thereof, fumarates and fumaronitriles, cinnamates and cinnamonnitriles, and stilbene.
- US 4,029,875 discloses an ethylene polymerisation process employing a mixture of organic peroxides and cyclic alkenes, styrene, or styrene
- 10 homologues bearing alkyl substituents on the benzene nucleus to reduce the consumption of initiator in the process and to improve the optical and mechanical properties of the polyethylene produced.

However, conventional phlegmatisers and stabilisers were often observed to
15 adversely effect the polymerisation process in which the peroxide composition was used. Accordingly, there is a need in the industry for packaged stabilised peroxide formulations that can be produced, handled, and shipped in a safe manner and where the stabilised peroxide formulations can safely be used in polymerisation reactions without any adverse effect. Preferably, use is made of
20 specific stabilised peroxide formulations that lead to a reduction in the amount of undesired phlegmatising agent in the polymer (resin) that is produced with said formulations. Conventional phlegmatising agents are not suitable for this function.

Surprisingly, it has now been found that the use of a specific phlegmatising
25 agent in a (stabilised) peroxide composition results in a final composition that shows good stability, milder effects in the decomposition of the peroxide, and no adverse effect in the polymerisation process. In addition, polymers, e.g. PVC, prepared using a peroxide composition of the invention, show unexpected properties regarding morphology, processing and stability. The use of an olefin


as phlegmatising agent has such a positive influence on the decomposition behaviour of the peroxide composition that, depending on the circumstances, it can be handled, produced, and shipped at higher temperatures than a conventional stabilised peroxydicarbonate composition. In addition, when a


5 (stabilised and) phlegmatised peroxide composition of the present invention is used in a polymerisation reaction, the phlegmatiser of the invention preferably is "consumed" (i.e. the olefin is a reactive phlegmatiser) during the polymerisation reaction, which gives the benefit of reduced unbound phlegmatiser in the polymer (so that the polymer contains less volatile product).

10 The reduced unbound phlegmatiser levels improve the organoleptic properties of the resulting (co)polymer and may even obviate a treatment of the polymer to reduce volatile material.


Accordingly, we claim 1) specific peroxide compositions that comprise i) 15 optionally a stabiliser; and ii) an specific agent as phlegmatising agent; 2) the production, handling, and shipping of such peroxide compositions which is more safe; and 3) the use of these peroxide compositions in polymerisation processes.

The peroxides that can be used for the compositions according to the invention are specific well-known compounds of which many are commercially available. 20 The peroxides are preferably liquid at the temperature at which they are produced, handled, or shipped. If the peroxides are not liquid they may be dissolved in a solvent, or a mixture of solvents. The peroxides are used as initiators in free radical polymerisation processes, and they are of the structural formulae:





(Formula II), and/or



(Formula III)

wherein R and R' represent organic groups. R and R' generally each have 1 to 20 carbon atoms, preferably 2 to 18 carbon atoms, and more preferably 2 to 16 carbon atoms. Preferably, R and R' represent branched or non-branched, substituted or unsubstituted alkyl, alkenyl or cycloalkyl groups. As suitable substituents may be mentioned aromatic groups, halogen atoms, such as chlorine and bromine, nitro groups, aryloxy groups and alkoxy groups. As examples of R and R' may be mentioned methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, isobutyl, hexyl, octyl, 2-ethylhexyl, 1,1 dimethylpropyl, 1,1,3,3 tertramethylbutyl, 1,1 dimethyl-3-hydroxybutyl, lauryl, mirystyl, cetyl, stearyl, allyl, methallyl, crotyl, cyclohexyl, 4-tert-butylcyclohexyl, 4-tert-amylcyclohexyl, benzyl, 2-phenylethyl, 2-phenylbutyl, 2-phenoxyethyl, 2-methoxyethyl, 2-ethoxyethyl, and 3-methoxybutyl. Although R and R' are generally identical for the peroxides according to Formula I and Formula II, the invention is not limited to these symmetric peroxides. Specifically for products of Formula III, R preferably is selected such that products of the formula RCOOH are conventional acids such as neodecanoic, neononanoic, neoctanoic, neoheptanoic, and 2-ethyl-hexanoic acid.

For example, in the case of peroxydicarbonates of the Formula I, also asymmetric peroxydicarbonates such as isopropyl-sec-butyl-peroxydicarbonate, mixtures of asymmetric peroxydicarbonates, and mixtures of symmetric and asymmetric peroxydicarbonates, such as the mixtures of diisopropyl

peroxydicarbonate, di(sec-butyl) peroxydicarbonate and isopropyl-(sec-butyl) peroxydicarbonate as described in US 4,269,726 can be stabilised and phlegmatised according to the present invention. The peroxide compositions according to the invention preferably contain at least one peroxide of the

5 Formula I and/or Formula II. Most preferably the peroxide compositions according to the invention preferably comprise at least a peroxide according to formula I.

10 The stabiliser that is used according to the invention is any conventionally used stabiliser. The preferred stabiliser is a hydroperoxide, the most preferred stabiliser is tert-butyl hydroperoxide.

15 The specific compounds that are used as phlegmatiser, and preferably being reactive, are of the general formula $R''HC=CHR''$ (Formula IV), wherein R'' and R''' are independently selected from hydrogen and the group consisting of linear or branched, saturated or unsaturated C_1-C_{12} alkane moieties, and R'' and R''' may be connected to form a cyclic alkene, with the exception of cyclohexene. Preferably, R'' and R''' are such that no conjugated double bonds are present, such as in 1,3-dienes. Preferred phlegmatisers according to Formula IV are

20 selected from:

- the group of α -olefins consisting of 1-hexene, 1-heptene, 1-octene, 1-nonene, 1-decene, 1-undecene, and 1-dodecene,
- the group of cyclic alkenes consisting of cycloheptene, cyclooctene, and cyclododecene, and
- 25 • mixtures of any of the preferred phlegmatisers.

The use of α -olefins is more preferred. The most preferred α -olefinic phlegmatiser is 1-octene.

The phlegmatiser used in accordance with the present invention preferably reacts

efficiently in the polymerisation process employing the peroxide composition. The term "react efficiently" as used herein means that at least 25%, preferably at least 50%, and most preferably more than 75% by weight of the reactive phlegmatiser is reacted in the polymerisation process. In other words, in the most preferred 5 situation, less than 25% by weight of the phlegmatiser used in the process is extractable from the resin (without destruction of the resin). Since the peroxide compositions according to the invention are pre-eminently suited for use in conventional suspension vinyl chloride polymerisation processes, it is preferred that the phlegmatiser reacts at the conditions of said conventional processes, 10 which are typically conducted at temperatures of 40-80°C and pressures of up to 18 bara. Whether or not it is a reactive phlegmatiser is easily tested by checking the amount of unreacted phlegmatiser in the polymer. It is to be understood that the term "reactive phlegmatiser" does not relate to conventional phlegmatisers, which do not react and often plasticise the resulting resin.

15

Phlegmatised peroxide compositions, according to a preferred embodiment of the invention, comprise:

- from 20 to 95% by weight, based on the weight of the total composition (%w/w), of at least one peroxide of Formula I, optionally in combination with 20 at least one peroxide of the Formula II and/or III. Preferred peroxides are peroxydicarbonates (of Formula I) optionally combined with diacylperoxides (of Formula II). More preferred are just peroxydicarbonates. Even more preferred are liquid peroxydicarbonates. Most preferred are di(2-ethylhexyl) peroxydicarbonate, di(n-butyl) peroxydicarbonate, and di(sec-butyl) peroxydicarbonate,
- from 0 to 1%w/w of stabiliser. Preferably the amount of stabiliser is from 0.05 to 0.5%w/w, and most preferably from 0.1 to 0.3%w/w. The preferred stabiliser is a hydroperoxide, the most preferred stabiliser is tert-butyl hydroperoxide,

- from 5 to 90%w/w of phlegmatising agent according to Formula IV, more preferably this amount is from 10 to 75%w/w, and most preferably from 15 to 60%w/w. Preferred phlegmatising agents are selected from the group of cyclo alkenes (with the exception of cyclohexene), and/or olefins. More preferred phlegmatiser is an α -olefin. The most preferred α -olefinic phlegmatiser is 1-octene, and
- from 0 to 50%w/w of optional conventional phlegmatisers, up to a total of 100%.

10 In another preferred embodiment, the invention relates to phlegmatised peroxide compositions wherein the selection of peroxide(s) is limited to the group of diacylperoxides (of Formula II) and/or peroxyesters (of Formula III), comprising optionally, but preferably, at least 0.01 to 1%w/w of one or more substances that have a stabilizing effect on the decomposition rate of a peroxide, which are 15 phlegmatised with an agent of Formula IV..

The peroxide compositions are prepared in a conventional way by mixing the stabiliser (if used), one or more peroxides, and phlegmatising agent in any sequence at temperatures below the SADT of the peroxides. Alternatively, the 20 peroxide is produced in the phlegmatising agent, requiring just the optional mixing in of the stabiliser.

The invention is elucidated by the following examples.

Experimental

The thermal stability was tested using the mini Heat Accumulation Storage Test (m-HAST). In this test, an appropriate sample (50 g) is put into a Dewar vessel (100 mL) and stored at a desired test temperature. During the test, the temperature of the sample is continuously measured. The experiment is stopped after a runaway occurred, or after a specified maximum time (i.e. no runaway).

10

Example 1 and Comparative Examples A-B

Trigonox® EHPS (di-2-ethylhexyl peroxydicarbonate that is stabilised with tert-butyl hydroperoxide) ex Akzo Nobel was combined with conventional phlegmatiser, i.e. isododecane or cyclohexene (comparative examples A-B), or

15 with a phlegmatiser according to the invention, i.e. 1-octene (example 1).

Example	A	B	1
Peroxydicarbonate + amount ¹⁾ of phlegmatiser	Trigonox® EHPS + 75%w/w isododecane	Trigonox® EHPS + 75%w/w cyclohexene	Trigonox® EHPS + 75%w/w 1-octene
m-HAST at	15°C	15°C	15°C
Induction time before decomposition (hours)	90	no runaway	no runaway
Thermal Explosion Vessel (TEV) max. pressure (barg)	6	6	4
Dutch Pressure Vessel test	3.5	3.5	3.0
Performance in PVC polymerisation kinetics	good	unacceptable	good

1) based on the weight of the total composition (%w/w)

Example 2 and Comparative Examples C-D

Unstabilised di-2-ethylhexyl peroxydicarbonate (Trigonox® EHP) ex Akzo Nobel

5 was combined with a conventional phlegmatiser, i.e. isododecane or cyclohexene (comparative examples C-D), or with a phlegmatiser according to the invention, i.e. 1-octene (example 2).

Example	C	D	2
Peroxydicarbonate + amount ¹⁾ of phlegmatiser	Trigonox® EHP + 75%w/w isododecane	Trigonox® EHP + 75%w/w cyclohexene	Trigonox® EHP + 75%w/w 1-octene
m-HAST at	15°C	15°C	15°C
Induction time before decomposition (hours)	11	no runaway	no runaway
Thermal Explosion Vessel (TEV) max. pressure (barg)	5	5	3
Dutch Pressure Vessel test	3.5 mm	3.0 mm	3.0 mm
Performance in PVC polymerisation kinetics	good	not acceptable	good

10 1) based on the weight of the total composition (%w/w)

Unexpectedly, the combination of stabilised and unstabilised peroxydicarbonate and the α -olefinic phlegmatising agent 1-octene (Examples 1-2) resulted in compositions having (all compared to similar peroxide compositions wherein

15 conventional phlegmatiser was used (Comparative examples A-B & C-D)):

- Higher runaway temperature.
- Longer induction time before the decomposition.

10

- Expected lower heat production at or above storage temperatures.
- Lower pressure build-up during the decomposition at or above storage temperatures.
- Good performance in PVC polymerisation kinetics.

5


Also, when these peroxide compositions of the present invention were used in a conventional suspension polymerisation of vinyl chloride monomer, it was observed that:

- Less volatiles were found in the PVC.
- 10 • PVC was obtained with unexpected properties regarding morphology, processing and stability.



Claims

1. A peroxide composition that comprises:

- at least one peroxide of the formula:



, and optionally at least one peroxide of the formulae:




10 wherein R and R' are independently selected from branched or non-branched, substituted or unsubstituted alkyl, alkenyl, or cycloalkyl C₁-C₂₀ hydrocarbon moieties,

- optionally at least one substance that has a stabilising effect on the decomposition rate of a peroxide, and
- at least one phlegmatising agent selected from the group of unsaturated compounds of the general formula R"HC=CHR'" wherein R" and R'" are independently selected from hydrogen and the group consisting of linear or branched, substituted or unsubstituted, saturated or unsaturated C₁-C₁₂ alkane moieties, and R" and R'" may be connected to form a cyclic structure, with the exception of cyclohexene.

15


20 2. A peroxide composition that comprises:

- at least one peroxide of the formulae:





wherein R and R' are selected from the group of hydrocarbon moieties according to the definition as described in claim 1,

- 5 • optionally at least one substance that has a stabilising effect on the decomposition rate of a peroxide, and
- at least one phlegmatising agent selected from the group of unsaturated compounds of the general formula R"HC=CHR'" wherein R" and R'" are independently selected from hydrogen or the group of alkane moieties according to the definition as described in claim 1.
- 10
- 3. A composition according to claim 1 or 2 wherein the unsaturated phlegmatising agent is selected from the group of 1-hexene, 1-heptene, 1-octene, 1-nonene, 1-decene, 1-undecene, 1-dodecene, cyclooctene, and cyclodecene, or mixtures thereof.
- 15
- 4. A composition according to any one of claims 1-3 wherein the unsaturated phlegmatising agent is 1-octene.
- 20
- 5. A composition according to claim 1 wherein the peroxide composition comprises:
 - from 20 to 95% by weight, based on the weight of the total composition (%w/w), of at least one peroxide of the formula:



, and optionally at least one peroxide of the formulae:





5 wherein R and R' are independently selected from the group of hydrocarbon moieties according to the definition as described in claim 1,

- from 0 to 1 %w/w of at least one substance that has a stabilizing effect on the decomposition rate of a peroxide,
- 10 • from 90 to 5%w/w of at least one phlegmatising agent selected from the group of unsaturated compounds according to the definition as described in claim 1, said phlegmatising agent preferably being reactive enough to react effectively in the polymerisation process, and
- from 0 to 50%w/w of at least one optional conventional phlegmatising agent,

15 up to a total of 100%.

6. A composition according to claim 2 wherein the peroxide composition comprises:

- 20 • from 20 to 95% by weight, based on the weight of the total composition (%w/w), of at least one peroxide of the formulae:



wherein R and R' are independently selected from the group of hydrocarbon moieties according to the definition as described in claim 1,

- 5 • optionally from 0.01 to 1 %w/w of at least one substance that has a stabilizing effect on the decomposition rate of a peroxide,
- from 90 to 5%w/w of at least one phlegmatising agent selected from the group of unsaturated compounds according to the definition as described in claim 1, said phlegmatising agent preferably being reactive enough to react effectively in the polymerisation process, and
- 10 • from 0 to 50%w/w of at least one optional conventional phlegmatisers, up to a total of 100%.

- 7. A method to produce a polymer by means of a radical polymerisation process involving the step of using a peroxide composition according to any one of claims 1-6.

- 15 8. A method to produce a polymer according to claim 7, wherein the polymerisation conditions are selected such that at least 25%w/w of the reactive phlegmatiser that was used is not extractable from the polymer.

- 20 9. A method to safely produce, transport, and otherwise handle a peroxide composition by selecting a phlegmatised, and optionally stabilised composition according to any one of claims 1-6.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/06339

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07C409/32 C07C409/38 C08F4/32 C08F4/38

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C07C C08F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	EP 1 216 991 A (AKZO NOBEL NV) 26 June 2002 (2002-06-26) the whole document ---	1-9
Y	US 4 029 875 A (GLORIODE PIERRE ET AL) 14 June 1977 (1977-06-14) cited in the application the whole document ---	1-9
Y	US 4 131 728 A (PRIDDY DUANE B) 26 December 1978 (1978-12-26) cited in the application the whole document ---	1-9
Y	WO 93 25615 A (DOW CHEMICAL CO) 23 December 1993 (1993-12-23) claims ---	1-9
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

17 September 2003

Date of mailing of the international search report

25/09/2003

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax. (+31-70) 340-3016

Authorized officer

Bonnevalle, E

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/06339

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6 399 728 B1 (MYERS TERRY N ET AL) 4 June 2002 (2002-06-04) claims -----	1-9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/06339

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
EP 1216991	A	26-06-2002	WO 02051802 A1 EP 1216991 A1 EP 1343755 A1 US 2002091214 A1	04-07-2002 26-06-2002 17-09-2003 11-07-2002
US 4029875	A	14-06-1977	FR 2308645 A1 BE 840965 A1 BR 7602468 A CS 191301 B2 DE 2616777 A1 DK 179476 A GB 1504245 A IE 43093 B1 IT 1070212 B JP 1280524 C JP 51135988 A JP 60003085 B LU 74793 A1 NL 7604215 A PT 65008 A ,B SU 667146 A3	19-11-1976 16-08-1976 19-10-1976 29-06-1979 11-11-1976 23-10-1976 15-03-1978 17-12-1980 29-03-1985 13-09-1985 25-11-1976 25-01-1985 12-01-1977 26-10-1976 01-05-1976 05-06-1979
US 4131728	A	26-12-1978	US 4178263 A	11-12-1979
WO 9325615	A	23-12-1993	AU 666094 B2 AU 4397793 A CA 2134967 A1 EP 0644916 A1 JP 7507797 T US 5347055 A WO 9325615 A1	25-01-1996 04-01-1994 23-12-1993 29-03-1995 31-08-1995 13-09-1994 23-12-1993
US 6399728	B1	04-06-2002	CA 2368277 A1 EP 1231206 A1 HU 0200382 A2 JP 2002302480 A NO 20020524 A US 2002177678 A1 AU 9718401 A	01-08-2002 14-08-2002 28-12-2002 18-10-2002 02-08-2002 28-11-2002 08-08-2002

CORRECTED VERSION

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
31 December 2003 (31.12.2003)

PCT

(10) International Publication Number
WO 2004/000799 A1

(51) International Patent Classification: C07C 409/32, 409/38, C08F 4/32, 4/38

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:
PCT/EP2003/006339

(22) International Filing Date: 13 June 2003 (13.06.2003)

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

(30) Priority Data:
60/390,799 20 June 2002 (20.06.2002) US

Published:

— with international search report

(71) Applicant: AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL).

(48) Date of publication of this corrected version:

25 March 2004

(72) Inventors: VANDUFFEL, Koen, Antoon, Cornelis; Stevinhof 18, NL-7424 AH Deventer (NL). TAMMER, Marinus, Catharinus; Umgrovelaan 7, NL 7431 ZA Diepenveen (NL). WAANDERS, Petrus, Paulus; Bentinckstraat 13, NL-7471 SL Goor (NL). VAN SWIETEN, Andreas, Petrus; Reinaldstraat 6, NL-6883 HM Velp (NL).

(15) Information about Correction:

see PCT Gazette No. 13/2004 of 25 March 2004, Section II

(74) Agent: SCHALKWIJK, Pieter, Cornelis; Akzo Nobel N.V., Intellectual Property Department (Dept. AIP), P.O. Box 9300, NL-6800 SB Arnhem (NL).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/000799 A1

(54) Title: (STABILISED) PEROXIDE COMPOSITIONS PHLEGMATISED WITH A SPECIFIC UNSATURATED PHLEGMATISING AGENT

(57) Abstract: The invention relates to peroxide compositions that are phlegmatised with a specific unsaturated phlegmatising agent. The phlegmatised peroxide compositions are optionally stabilised. In addition, the invention relates to the safe handling of these peroxide compositions and the use of these peroxide compositions in polymerisation processes..